

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

12-2002: Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb

Clonality: Monoclonal
Application: ELISA
Reactivity: Human
Isotype: IgG4

Description

Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils, lymphocytes, macrophages, monocytes, natural killer (NK) cells, and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway, leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.

Product Info

Amount : 100 μg

Purification: Purified from cell culture supernatant by affinity chromatography **Storage condition:** Store at -20°C to -80°C (Avoid repeated freezing and thawing).

Application Note

ELISA 1:5000-10000, FACS 1:100




Fig.1: Coomassie staining of SDS PAGE gel loaded with 5ug of Anti-IL-17A (Ixekizumab biosimilar) mAb (Abeomics cat# 12-2002)